Disorders due to widespread death of bone matrix, osteonecrosis, and focal or systemic bone thickening are reviewed here. Osteonecrosis is a common problem and may be caused by trauma, with direct damage to blood vessels supporting bone or due to fractures that interrupt vascular supply. Osteonecrosis is also caused by metabolic imbalance, commonly due to glucocorticoid administration with secondary ACTH suppression, receptors for both of which are important in bone. Osteonecrosis also occurs with bone-binding antimetabolites, and bisphosphonate osteonecrosis, particularly of the jaw, is an important problem where type and length of treatment affect likelihood of the complication. Sclerotic disorders generally reflect local or systemic changes in bone morphogenetic protein signaling or other signals including sclerostin. Benign focal ossification and several rare diseases reflect this imbalance, including fibrodysplasia ossificans progressiva (FOP), sclerosteosis, osteopoikilosis, and melorheostosis.1. Focal osteonecrosis occurs as a consequence of metabolic or traumatic events. Trauma that interrupts the blood supply to a bone, such as the femoral head, causes osteonecrosis. Regions with abundant trabecular bone are subject to osteonecrosis with disruption of microvascular support by high glucocorticoids especially when ACTH is depressed. Joint replacement is often required. Regions of bone that normally have low turnover, such as the femoral or mandibular cortex, are subject to necrosis in bisphosphonate toxicity. Conditions that increase the likelihood of osteonecrosis should be avoided.2. Myositis ossificans circumscripta, or traumatica, and other heterotopic ossification events are manifest as focal calcification, often with differentiation of true bone, usually at sites of injury. Usually no management is required, although surgical excision may be useful. Localized TGF-β and activin activity has been noted during the development of these lesions.3. FOP is a rare, aggressive disease where many tissues calcify progressively. Most, if not all, of the cases have a constitutively active BMP type I receptor subunit, the activin-like kinase 2. Management is very difficult; attempts to reverse activin signaling are in development.4. Rare diseases with focal cortical thickening may be systemic or local. The syndromes need to be identified as nonmalignant, but specific therapy is not available; symptomatic treatment may be required. Systemic forms include osteosclerosis due to sclerostin defects with diffuse cortical thickening. Osteopoikilosis, characterized by scattered foci of thick bone, is usually associated with dominant mutations in the LEMD3 gene, which regulates BMP signaling. Melorheostosis is an acquired disorder with focal or segmental thickening of the bone cortex likened to dripping candle wax without a known mechanism. It usually involves a segmental region of the skeleton or one bone and may cause deformity and local functional defects in mobility or circulation.
Read full abstract